PFNX - A Look At Merck's Keytruda And Other Headlines: The Good Bad And Ugly Of Biopharma
According to industry and sector data analysed by GlobalData, Merck's (MRK) Keytruda will reportedly become the world's top-selling drug by 2025, with estimated sales of over $22 billion. Wall Street consensus estimate pegs nearly $20 billion annual sales for Keytruda by 2023. Bristol-Myers Squibb's (BMS) drug Opdivo that is the major competitor to Keytruda will be the fourth highest global seller, according to the GlobalData analysis. This is ironic because it was BMS's work in anti-PD-1 molecules that forced Merck to revive its Keytruda program. Keytruda (pembrolizumab), which boosts the immune system by